

Selective Laser Trabeculoplasty

ZEISS VISULAS combi and ZEISS VISULAS green with SLT



Compendium of peer-reviewed journal articles
September 2025



Seeing beyond

Table of Contents

Prospective studies

ZEISS VISULAS SLT 3

1. Effectiveness and safety of VISULAS green selective laser trabeculoplasty: a prospective, interventional multicenter clinical investigation
2. ZEISS VISULAS green SLT in primary open-angle glaucoma and ocular hypertension: 6-month follow-up in a real-world setting

Others 3

3. Selective laser trabeculoplasty for early glaucoma: analysis of success predictors and adjusted laser outcomes based on the untreated fellow eye
4. Automated Direct Selective Laser Trabeculoplasty: First Prospective Clinical Trial (2021)

Retrospective studies

ZEISS VISULAS SLT 4

5. Effectiveness and safety of VISULAS green selective laser trabeculoplasty: 12 months retrospective data
6. Real-world results of the ZEISS selective laser trabeculoplasty in adult South African primary open-angle glaucoma patients

Others 4

7. Outcome after Selective Laser Trabeculoplasty for Glaucoma Treatment in a Thai Population
8. Selective laser trabeculoplasty for early glaucoma: analysis of success predictors and adjusted laser outcomes based on the untreated fellow eye
9. Repeatability of selective laser trabeculoplasty for open-angle glaucoma
10. Direct selective laser trabeculoplasty: A retrospective study
11. Predictors of success in Selective Laser Trabeculoplasty: Data from the Lausanne Laser Trabeculoplasty Registry
12. Predictors of success in Selective Laser Trabeculoplasty
13. Real-world outcomes of selective laser trabeculoplasty in the United Kingdom

Randomized clinical trial studies

Others 5

14. Efficacy and safety of selective laser trabeculoplasty and pattern scanning laser trabeculoplasty: a randomized clinical trial
15. Comparing pattern scanning laser trabeculoplasty to selective laser trabeculoplasty: a randomized controlled trial
16. Direct selective laser trabeculoplasty: long-term safety and efficacy

Prospective studies

ZEISS VISULAS SLT

1. Pillunat K, Klabe K, Kretz F, Koinze S, Ehlken C, Pillunat L. **Effectiveness and safety of VISULAS green selective laser trabeculoplasty: a prospective, interventional multicenter clinical investigation.** *Int Ophthalmol.* 2023 Jul;43(7):2215-2224. <https://pubmed.ncbi.nlm.nih.gov/36572747/>
<https://link.springer.com/article/10.1007/s10792-022-02617-7>

Study spotlight: Treatment success rate (IOP reduction \geq 20%): 48.5%

https://asset-downloads.zeiss.com/catalogs/download/med2/782eeb45-064b-4252-9775-9af4d7645e0a/ZEISS-Study-Spotlight-LST_en-OUS_31_200_0329I.pdf

2. Sacchi M, Brancato C, Li Calzi G, Monsellato G, Nucci P, Tomaselli D. **ZEISS VISULAS green SLT in primary open-angle glaucoma and ocular hypertension: 6 month follow up in a real-world setting.** *Acta Ophthalmol.* 2024 Jan;102(S279):26-28. <https://onlinelibrary.wiley.com/doi/10.1111/aos.16203>

Study spotlight: Treatment success rate (IOP reduction \geq 20%): 52.9%

https://asset-downloads.zeiss.com/catalogs/download/med2/1f932ffc-1883-4bcf-8a53-5a46403491a8/Study-Spotlight-VISULAS-SLT-en-OUS_31_025_0829I.pdf

Others

3. Chun M, Biteli L, Gracitelli C, Lopes F, Prata T, Ushida M. **Selective laser trabeculoplasty for early glaucoma: analysis of success predictors and adjusted laser outcomes based on the untreated fellow eye.** *BMC Ophthalmol.* 2016 Nov 23;16(1):206. <https://pubmed.ncbi.nlm.nih.gov/27881155/>
<https://bmcophthalmol.biomedcentral.com/articles/10.1186/s12886-016-0385-z>
4. Goldenfield M, Belkin M, Dobkin-Bekman M, Geffen N, Leshno A, Meirovitch S, Sacks Z, Skaat A. **Automated Direct Selective Laser Trabeculoplasty: First Prospective Clinical Trial.** *Transl Vis Sci Technol.* 2021 Mar 1;10(3):5. <https://pubmed.ncbi.nlm.nih.gov/34003939/>
<https://tvst.arvojournals.org/article.aspx?articleid=2772356>

Retrospective studies

ZEISS VISULAS SLT

1. Pillunat K, Klabe K, Kretz F, Koinze S, Ehlken C, Pillunat L. **Effectiveness and safety of VISULAS green selective laser trabeculoplasty: 12 months retrospective data.** *Lasers Med Sci.* 2024 Dec 15;39(1):293. <https://pubmed.ncbi.nlm.nih.gov/39674816/>; <https://link.springer.com/article/10.1007/s10103-024-04252-3>
Study spotlight: Treatment success rate (IOP reduction \geq 20%): 52.6%
2. Church B, Wassermann P. **Real-world results of the ZEISS selective laser trabeculoplasty in adult South African primary open-angle glaucoma patients.** *Ther Adv Ophthalmol.* 2024 Dec. eCollection 2024 Jan-Dec. <https://pubmed.ncbi.nlm.nih.gov/39660036/>; <https://journals.sagepub.com/doi/10.1177/25158414241302891>
Study spotlight: At 6 months, about 60% of patients no longer needed any glaucoma medications. The reduction in medication did not compromise the control of IOP.
https://d7ig8g9lbiqy2.cloudfront.net/a00d02b8-72c4-4a42-a18c-1cc1dd9af2d7/a419e2ee-c38a-4e28-ab08-d3d07bf55871/a419e2ee-c38a-4e28-ab08-d3d07bf55871_viewable_rendition__v.pdf

Others

3. Funarunart P, Treesit I. **Outcome after Selective Laser Trabeculoplasty for Glaucoma Treatment in a Thai Population.** *Clin Ophthalmol.* 2021 Mar 18;15:1193-1200. eCollection 2021. <https://pubmed.ncbi.nlm.nih.gov/33776415/>; <https://www.dovepress.com/outcome-after-selective-laser-trabeculoplasty-for-glaucoma-treatment-i-peer-reviewed-fulltext-article-OPHTH>
4. Chun M, Biteli L, Gracitelli C, Lopes F, Prata T, Ushida M. **Selective laser trabeculoplasty for early glaucoma: analysis of success predictors and adjusted laser outcomes based on the untreated fellow eye.** *BMC Ophthalmol.* 2016 Nov 23;16(1):206. <https://pubmed.ncbi.nlm.nih.gov/27881155/>
<https://bmcophthalmol.biomedcentral.com/articles/10.1186/s12886-016-0385-z>
5. Francis B, Bacharach J, Dustin L, et al. **Repeatability of selective laser trabeculoplasty for open-angle glaucoma.** *BMC Ophthalmol.* 2016 Jul 28;16:128. <https://pubmed.ncbi.nlm.nih.gov/27464887/>
<https://bmcophthalmol.biomedcentral.com/articles/10.1186/s12886-016-0299-9>
6. Fossati G, Abdou H, Malick H, et al. **Direct selective laser trabeculoplasty: A retrospective study.** *Eur J Ophthalmol.* 2025 Jul;35(4):1329-1335. Epub 2024 Nov 25. <https://pubmed.ncbi.nlm.nih.gov/39587860/>
<https://journals.sagepub.com/doi/10.1177/11206721241301935>
7. Elahi S, Dumitru A, Mansouri K, Rao H. **Predictors of success in Selective Laser Trabeculoplasty: Data from the Lausanne Laser Trabeculoplasty Registry.** *J Glaucoma.* 2020 Jul;29(7):550-555. <https://pubmed.ncbi.nlm.nih.gov/32398589/>
https://journals.lww.com/glaucomajournal/abstract/2020/07000/predictors_of_success_in_selective_laser.8.aspx
8. Kuley B, Hamershock R, Lee D, et al. **Predictors of success in Selective Laser Trabeculoplasty.** *Ophthalmol Glaucoma.* 2020 Mar-Apr;3(2):97-102. Epub 2019 Nov 30. <https://pubmed.ncbi.nlm.nih.gov/32672601/>
<https://www.sciencedirect.com/science/article/abs/pii/S2589419619303515?via%3Dihub>
9. Khawaja A, Campbell J, Chandwani H, et al. **Real-world outcomes of selective laser trabeculoplasty in the United Kingdom.** *Ophthalmology.* 2020 Jun;127(6):748-757. <https://pubmed.ncbi.nlm.nih.gov/31952882/>
[https://www.aaajournal.org/article/S0161-6420\(19\)32298-5/fulltext](https://www.aaajournal.org/article/S0161-6420(19)32298-5/fulltext)

Randomized clinical trial studies

Other

1. Wong MOM, Chiu VSM, Lai ISW, et al. **Efficacy and safety of selective laser trabeculoplasty and pattern scanning laser trabeculoplasty: a randomized clinical trial.** *Br J Ophthalmol.* 2021 Apr;105(4):514-520. Epub 2020 Jun 30. <https://pubmed.ncbi.nlm.nih.gov/32606078/>; <https://bjo.bmj.com/content/105/4/514>
2. Mansouri K, Shaarawy T. **Comparing pattern scanning laser trabeculoplasty to selective laser trabeculoplasty: a randomized controlled trial.** *Acta Ophthalmol.* 2017 Aug;95(5):e361-e365. Epub 2016 Oct 25. <https://pubmed.ncbi.nlm.nih.gov/27778483/>; <https://onlinelibrary.wiley.com/doi/10.1111/aos.13280>
3. Cutolo C, Acerra S, Bagnis A, et al. **Direct selective laser trabeculoplasty: long-term safety and efficacy.** *Invest Ophthalmol Vis Sci.* 2023 Jun;64(8):4905. <https://iovs.arvojournals.org/article.aspx?articleid=2788828>



Carl Zeiss Meditec, Inc.

5300 Central Parkway
Dublin, CA 94568
USA
www.zeiss.com
www.zeiss.com/med/contacts



Carl Zeiss Meditec AG

Goeschwitzer Str. 51-52
07745 Jena
Germany
www.zeiss.com
www.zeiss.com/med/contacts

en-OUS_31_010_01471 CZ-IX/2025 International edition: Only for sale in selected countries.
The contents of this document may differ from the current status of approval of the product or service offering in your country. Please contact our regional representatives for more information. Subject to changes in design and scope of delivery and as a result of ongoing technical development. VISULAS is either a trademark or registered trademark of Carl Zeiss Meditec AG or other companies of the ZEISS Group in Germany and/or other countries.
© Carl Zeiss Meditec, Inc., 2025. All rights reserved.